News

The trial will evaluate the HIV patients who are using MVA85A, which is being developed by OETC, a joint venture between the University of Oxford and Emergent BioSolutions,

The company’s loss from operations for the second quarter of 2011 was $6.58m, compared to $4.3m for the same period in 2010. For the six months ended 30

The increase is related to comparative higher-than-normal deliveries of Cetrotide to certain customers, as well as to the comparative strengthening of the euro against the US dollar. The

The Veeva CRM suite of applications include VBioPharma, iRep, VMobile, and Vinsights. The new CRM system will facilitate Eisai to streamline its computing environment by integrating three of

The fund has been granted to the Israeli R&D subsidiary of Prolor for the biobetter version of human growth hormone, hGH-CTP. Prolor is responsible to pay back the

The agreement aims to develop adoptive cell immunotherapies that are intended to destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes. Under the CRADA, the companies will

The tie up allows GNS to use clinical and molecular information from a BMS clinical trial while using its own supercomputer-driven reverse-engineering and forward-simulation (REFS) platform for creating

The trials aim to determine the safety and efficacy profile of the drug in inflammatory disorders. Glenmark has also initiated another global Phase IIb trial with Revamilast in

Watson’s rosuvastatin zinc 5, 10, 20 and 40mg tablets are the generic version of Astrazeneca’s Crestor (rosuvastatin calcium) tablets. Crestor is indicated, as an adjunct to diet, to